Transoma Medical, Inc. has announced the first enrollment and implant of Sleuth AT in a long-term study to monitor patients who have suffered a cryptogenic stroke (of unknown origin) to determine if atrial fibrillation (AF) is present. Dr. Emile Daoud, electrophysiologist performed the first implant on April 10, 2009 at Ohio State University Medical Center in Columbus. The company received FDA 510(k) marketing clearance for Sleuth AT on Feb. 11, 2009. The Long-Term Cardiac Monitoring for Detection of Atrial Fibrillation after Cryptogenic Stroke is a pilot study involving five centers in Canada and the United States. The investigators driving this important clinical study are Dr. Andrew Krahn from the London Health Sciences Centre University Hospital in London, Ontario and Dr. Daoud. The primary endpoint of the study is to determine the incidence of AF at one year from Sleuth AT implantation in patients who have had cryptogenic stroke. The company’s Sleuth AT allows physicians to program the capture of high-quality ECG strips at frequent intervals, providing a new level of insight into complex arrhythmias which are often asymptomatic and frequently changing. These captured ECG strips are automatically transferred to a 24/7 monitoring center, staffed by certified cardiac technicians, who classify and notify physicians of the presence of a wide variety of cardiac arrhythmias such as ventricular tachycardia, bradycardia, supraventricular tachycardia and atrial fibrillation.